Ratings by Bloom Burton & Co. (David Martin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/9/2026 | Xenon Pharmaceuticals | XENE | Maintain | Buy (1) (N/A) |
|
Details | ||
| 2/24/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Buy (1) (N/A) |
8.50 (6.03) |
-29.06% | Details | |
| 12/16/2024 | ESSA Bancorp | ESSA | New Coverage | Hold (3) (N/A) |
20.49 (20.61) |
0.59% | Details | |
| 12/16/2024 | ESSA Pharma | EPIX | New Coverage | Hold (3) (N/A) |
1.64 (0.20) |
-87.8% | Details | |
| 5/3/2024 | Aurinia Pharmaceuticals | AUPH | Upgrade | Accumulate (2) (Hold (3)) |
5.17 (15.85) |
206.58% | Details | |
| 5/2/2024 | Cybin Inc. | CYBN | New Coverage | Buy (1) (N/A) |
0.35 (8.28) |
2265.71% | Details | |
| 3/20/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Hold (3) (Buy (1)) |
21.18 (21.55) |
1.75% | Details | |
| 2/16/2024 | Aurinia Pharmaceuticals | AUPH | Downgrade | Hold (3) (Buy (1)) |
6.02 (15.85) |
163.29% | Details | |
| 7/27/2022 | Aurinia Pharmaceuticals | AUPH | Downgrade | Accumulate (2) (Buy (1)) |
8.82 (15.85) |
79.71% | Details | |
| 5/7/2021 | Aurinia Pharmaceuticals | AUPH | Upgrade | Buy (1) (Accumulate (2)) |
12.34 (15.85) |
28.44% | Details | |
| 1/25/2021 | Aurinia Pharmaceuticals | AUPH | Maintain | Accumulate (2) (N/A) |
|
Details | ||
| 12/17/2020 | Fusion Pharmaceuticals | FUSN | New Coverage | Buy (1) (N/A) |
13.22 (21.55) |
63.01% | Details |
